Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
about
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciBad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaCeftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring STuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol.A novel STK1-targeted small-molecule as an "antibiotic resistance breaker" against multidrug-resistant Staphylococcus aureus.Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityMethicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsHeterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Current and novel antibiotics against resistant Gram-positive bacteriaCorrelation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operonsCutaneous infections and infestations: new therapiesFrequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial PeptidesTelavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.Mechanisms of resistance to daptomycin in Enterococcus faecium.The evaluation and treatment of complicated skin and skin structure infections.Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistancePre-clinical experience with daptomycin.High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure.Daptomycin in bone and joint infections: a review of the literature.β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.Infectious complications in dialysis--epidemiology and outcomes.Roles of tRNA in cell wall biosynthesis.Staphylococcus aureus chronic and relapsing infections: Evidence of a role for persister cells: An investigation of persister cells, their formation and their role in S. aureus disease.Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.
P2860
Q26853465-AC5C8029-B69A-473C-B514-D9BD6F7F4B06Q29616084-C4902BAE-CDE5-45C5-A553-E7CADBECC602Q30452801-1778DE86-387C-41F9-9CC8-5B81B440AE62Q31131146-BB65337F-AA12-48E3-AAE0-BED25C39A440Q31164789-B50B8E06-2DFC-49E1-BC51-A942F291DADFQ33507347-63A472BC-6820-4FF9-930B-B11F3C81EFE8Q33894853-1E0FE71E-3784-4BAD-A891-18AAF68B8971Q33939055-37A17A19-3838-4D52-9929-FB547C124B40Q33970752-5400D8AC-7D0B-4302-837D-B6205EFF956DQ33997671-1722E25F-F92F-49D9-93F2-7E5A9CB79875Q34045273-DCCAE401-DFF4-47FF-B7EB-B9003E6FC482Q34045376-B0694047-3EA6-43D0-89C7-4E82E344C983Q34157657-D3C2279B-8E74-4280-9A3D-431689383836Q34529205-34315BB3-7FDE-4AB9-8CCC-35B1F8161ACBQ34573702-EF4A1E86-DC6E-4521-9CF3-413202455976Q34597770-F2924D05-FFCC-459C-BE6A-6E3704067333Q34779009-0C254CD3-649A-480C-9C6F-B29D22F529BDQ34932588-8A86DBD7-BC11-450E-A0D2-7DE4CD2F9D6EQ35026521-8D6428F3-9608-4915-B42A-0A16BBA4188BQ35139449-ECCBAF53-2790-4275-B074-6F00B21C3887Q35256159-0D273290-AD17-4A4C-9A82-72863A4C839AQ35628618-64AA348B-72B8-4AD5-8955-8D06A6995A45Q35860154-1BDE2E38-9FEC-4FA7-A85C-D6636E1EF997Q36364106-C25F64A8-D34F-4E82-941B-793FC7467945Q36482920-399D0B1D-BB9C-42C4-B043-C179E511E381Q37111836-8B238858-6156-4923-9E8F-6556BE464954Q37263514-6E3E2516-0950-4505-A606-8BA10983AD53Q37284356-1CCBD555-C823-4B34-825D-FD97E1731883Q37291084-4C55BB2A-3AD6-4D47-9D04-3F8257B046FDQ37319460-7FC9AC12-15D1-4CD8-A3B2-827FF19CFDF3Q37544579-2C5623AB-0988-45B0-B1DD-EB886840E613Q37969996-7512F4D6-DA93-435E-BE25-7C8B5638CD8CQ37977400-8B89791D-24BF-47C0-A92E-6CE827804096Q38237595-C8C66A7F-E13C-4CB3-A761-C548548AADC9Q38369089-B2628141-4E11-4641-8073-9E35D75521EBQ38530316-C54E5957-34E9-4C9A-B4D4-97BF710E3021Q38626860-82836823-7166-47A3-A205-166D18F2EE40Q38627239-CBA163BB-FDB2-485E-A05D-896C65241E90Q38895642-751042D8-11F4-452E-AA36-39F0A8FBE306Q39000860-33656118-97D4-4D74-B8E1-CFE162945B0D
P2860
Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.
@en
type
label
Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.
@en
prefLabel
Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.
@en
P2860
P356
P1476
Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.
@en
P2093
George Sakoulas
Helen W Boucher
P2860
P304
P356
10.1086/520655
P407
P577
2007-08-01T00:00:00Z